The purpose is to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
40
single intravenous infusion of 10 mg PF-04427429 or placebo
single intravenous infusion of 30 mg PF-04427429 or placebo
single intravenous infusion of 100 mg PF-04427429 or placebo
Pfizer Investigational Site
Brussels, Belgium
Adverse events, Vitals, ECG, laboratory safety tests, IV infusion site reaction
Time frame: up to 84 days
Plasma pharmacokinetics of PF-04427429
Time frame: up to 84 days
Free and total CGRP plasma concentrations
Time frame: up to 84 days
anti-drug antibody
Time frame: up to 84 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
single intravenous infusion of 300 mg PF-04427429 or placebo
single intravenous infusion of 1000 mg PF-04427429 or placebo